Use of statins for enhancing bone-tissue-engineered grafts
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : S. L. Griffiths & S. H. Cartmell
- چاپ و سال / کشور: 2007
Description
Bone tissue engineering is a potential emerging therapy for patients suffering from bone loss as a result of trauma or disease. Statins are a commonly prescribed cholesterol-lowering drug; however, it has recently been shown that they also have the beneficial side effect of enhancing bone matrix formation. This study has looked at using this bone-enhancing effect of statins for the novel use in enhancing bone-tissue-engineered grafts. Primary human osteoblasts (hOBs) were seeded in 2D culture onto a sixwell plate and cultured for 1 week with 5 ىM simvastatin added as a supplement to media. The effects on gene expression were then measured using quantitative real-time reverse transcriptase–polymerase chain reaction. Cells were also seeded for 3D culture onto poly-L-lactide scaffolds and cultured in vitro with 5 ىM simvastatin over a 7-week period. The volume and location of the mineralised matrix were measured using a microcomputed tomography (microCT) scanner and the rate of proliferation measured via PicoGreen analysis. Results from the 2D study showed a significant increase in expression of osteopontin and bone-morphogenic protein-2, whilst significantly downregulating other typical bone-related genes. The 3D study showed an increase in mineralised matrix being produced per osteoblast when microCT data were normalised to PicoGreen DNA data. Our results suggest that statins have the potential to be utilised for bone tissue engineering strategies. Further optimisation is now needed on the timing of the statin dose administration.
Eur J Plast Surg DOI 10.1007/s00238-007-0190-2 Received: 12 June 2007 / Accepted: 5 July 2007
